CERo Therapeutics Holdings, Inc.

What they do

CERo Therapeutics Holdings, Inc. (f/k/a Phoenix Biotech Acquisition Corp.) is an immunotherapy company advancing next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary T cell engineering approach aims to integrate characteristics of both innate and adaptive immunity into a single therapeutic construct designed to engage the body's full immune repertoire. The company is in early clinical development and has not yet begun product commercialization, with efforts focused on continued product development and clinical development to support regulatory approval.

Revenue drivers

• No product revenue — As of the six months ended June 30, 2026, the company reported no revenues; it is an early clinical development-stage business with no commercialized products.
• Pre-commercial pipeline — The company's engineered T cell therapeutic construct is still in development and has not generated any revenue; future revenue would depend on regulatory approval and commercialization.

Recent performance

For the six months ended June 30, 2026, the company reported a net loss of $6.9 million and used approximately $5.1 million of net cash in operating activities, with no revenues. As of June 30, 2026, it reported approximately $937,512 of cash, restricted cash, and cash equivalents, a working capital deficit of approximately $30.9 million, total assets of $1.9 million and total liabilities of $32.4 million. Stockholders' deficit was approximately $30.5 million at June 30, 2026, with an accumulated deficit of approximately $97.8 million. Annual net loss grew from $7.7 million in 2024 to $19.9 million in 2025, while operating cash outflow was $16.1 million in 2025.

Strategy

Management states that efforts will focus on continued product development, including clinical development, to support regulatory approval and subsequent commercialization. During the six months ended June 30, 2026, the company received net proceeds of $700,491 from common stock sales under ELOC fundings and issued convertible notes with an aggregate principal face value of $4,579,500, receiving net proceeds of $3,663,600. The company acknowledged that additional funds are necessary to maintain current operations and continue R&D activities. A series of 8-K filings between February and August 2026 report entry into material agreements, direct financial obligations, and unregistered equity sales, indicating reliance on ongoing financings.

Risks

• Going concern — Management states the company's conditions raise substantial doubt about its ability to continue as a going concern within one year from the issuance of the June 30, 2026 financial statements.
• Funding need — Additional funds are necessary to maintain operations and continue R&D; without sufficient funding, significant spending reductions and delay or cancellation of planned activities may be required.
• No approved product — The company is in early clinical development with no product commercialization and no revenues, so future revenue depends entirely on successful development, FDA approval and commercialization.
• Accumulated deficit and working capital deficit — As of June 30, 2026, the company reported an accumulated deficit of approximately $97.8 million, stockholders' deficit of $30.5 million, and a working capital deficit of approximately $30.9 million.

Outlook

Management says the company will focus on continued product development, including clinical development, to support regulatory approval and eventual commercialization. It also states that additional funds are necessary to maintain current operations and continue R&D, and that there is no assurance sufficient funding will be available for planned R&D activities and FDA regulatory filings. The financial statements do not include adjustments that might result from the outcome of the going concern uncertainty.